Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9

OBJECTIVE(S): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Iran J Basic Med Sci
Egile Nagusiak: Ebrahimi, Saeedeh, Makvandi, Manoochehr, Abbasi, Samaneh, Azadmanesh, Kayhan, Teimoori, Ali
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Mashhad University of Medical Sciences 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7395182/
https://ncbi.nlm.nih.gov/pubmed/32774817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/ijbms.2020.43864.10286
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak